2013
DOI: 10.1016/j.humpath.2013.04.011
|View full text |Cite
|
Sign up to set email alerts
|

IMP3 as a supplemental diagnostic marker for Hodgkin lymphoma

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
15
0

Year Published

2014
2014
2023
2023

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 21 publications
(15 citation statements)
references
References 28 publications
0
15
0
Order By: Relevance
“…Therefore, it is tempting to speculate that IGF2BP3 is a direct transcriptional target of MLL fusion proteins. However, IGF2BP3 is also overexpressed in most of the B-ALL cell lines tested, various mature B cell neoplasms (34)(35)(36)(37), and a number of epithelial malignancies. Furthermore, differential regulation of this protein has been observed in B-ALL (38).…”
Section: Discussionmentioning
confidence: 99%
“…Therefore, it is tempting to speculate that IGF2BP3 is a direct transcriptional target of MLL fusion proteins. However, IGF2BP3 is also overexpressed in most of the B-ALL cell lines tested, various mature B cell neoplasms (34)(35)(36)(37), and a number of epithelial malignancies. Furthermore, differential regulation of this protein has been observed in B-ALL (38).…”
Section: Discussionmentioning
confidence: 99%
“…Studies investigating lung cancer have shown that IGF2BP3 is immunogenic as assessed by the presence of an antibody against recombinant IGF2BP3 in lung pleural effusions (Wang et al, 2003), and immunogenic peptides derived from IGF2BP3 induce tumor-reactive and human leukocyte antigen (HLA)-A2 (A * 02:01)-restricted cytotoxic T lymphocytes (CTL) (Tomita et al, 2011). More recently, cancer vaccination using the IGF2BP3 508-516 peptide along with the LY6K 177-186 and CDCA1 56-64 peptides was tested in a phase II open-label, non-randomized clinical trial in head and neck squamous cell Hodgkin lymphoma Tang et al (2013) cancer patients, indicating that a vaccination-induced immune response was positively correlated with a better prognosis (Yoshitake et al, 2015).…”
Section: Potential Relevance Of Igf2bp3 In Therapymentioning
confidence: 99%
“…IMP3 is absent in almost all healthy, adult tissues. However, expression of IMP3 could be observed in several kinds of cancer like in colon carcinoma ( Li et al, 2009 ; Lochhead et al, 2012 ; Kumara et al, 2015 ), adenocarcinomas ( Bellezza et al, 2009 ; Lu et al, 2009 ; Gao et al, 2014 ), urothelial carcinomas ( Sitnikova et al, 2008 ; Xylinas et al, 2014 ), lymphomas ( King et al, 2009 ; Tang et al, 2013 ; Hartmann et al, 2012 ) or renal cell carcinomas ( Hoffmann et al, 2008 ; Jiang et al, 2006 ; Jiang et al, 2008 ).…”
Section: Discussionmentioning
confidence: 99%
“…Besides the critical role of IMP3 in fetal development ( Mueller-Pillasch et al, 1999 ) and fertility ( Li et al, 2014 ; Hammer et al, 2005 ), its importance as an oncogene in several kinds of cancer was determined in the last few years: Expression of IMP3 could be observed in colon carcinoma ( Li et al, 2009 ; Lochhead et al, 2012 ; Kumara et al, 2015 ), adenocarcinomas ( Bellezza et al, 2009 ; Lu et al, 2009 ; Gao et al, 2014 ), urothelial carcinomas ( Sitnikova et al, 2008 ; Xylinas et al, 2014 ), lymphomas ( King et al, 2009 ; Tang et al, 2013 ; Hartmann et al, 2012 ), renal cell carcinomas ( Hoffmann et al, 2008 ; Jiang et al, 2006 ; 2008 ), and many more ( Hammer et al, 2005 ; Chen et al, 2013 ; Walter et al, 2009 ; Köbel et al, 2009 ; Zhou et al, 2014 ). Additionally, high expression of IMP3 often correlates with poor survival prognosis for patients ( Hoffmann et al, 2008 ; Jiang et al, 2006 ; Köbel et al, 2009 ; Yuan et al, 2009 ; Lin et al, 2013 ).…”
Section: Introductionmentioning
confidence: 99%